4//SEC Filing
Singh Nikhilesh N 4
Accession 0001181431-09-006284
CIK 0001178711other
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 6:47 PM ET
Size
18.3 KB
Accession
0001181431-09-006284
Insider Transaction Report
Form 4
Singh Nikhilesh N
SVP & Chief Scientific Officer
Transactions
- Award
Common Stock
2009-01-30+235→ 295 total(indirect: See footnote) - Award
Employee stock option (right to buy)
2009-01-30+59,598→ 59,598 totalExercise: $0.88Exp: 2016-03-15→ Common Stock (59,598 underlying) - Award
Common Stock Warrant
2009-01-30+307→ 307 totalExercise: $8.14Exp: 2012-10-25→ Common Stock (307 underlying) - Award
Common Stock
2009-01-30+13,237→ 13,437 total - Award
Common Stock
2009-01-30+78,206→ 78,206 total(indirect: See footnote) - Award
Common Stock
2009-01-30+36,709→ 36,709 total(indirect: See footnote) - Award
Employee stock option (right to buy)
2009-01-30+102,088→ 102,088 totalExercise: $1.77Exp: 2017-04-04→ Common Stock (102,088 underlying)
Footnotes (9)
- [F1]Pursuant to the Agreement and Plan of Merger by and among Novacea, Inc. ("Novacea"), Pivot Acquisition, Inc. and Transcept Pharmaceuticals, Inc. ("Transcept"), dated as of August 29, 2008 (the "Merger Agreement"), each share of Transcept common stock converted into 0.141340 shares of Novacea common stock at the effective time of the merger. After completion of the merger, Novacea was renamed Transcept Pharmaceuticals, Inc. and began to trade under the stock symbol TSPT.
- [F2]Shares held directly by the Reporting Person's spouse.
- [F3]Shares held directly by the Singh Family Trust (the "Family Trust") for which Reporting Person's spouse serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by the Family Trust except to the extent of his pecuniary interest therein.
- [F4]Shares held directly by the Nikhilesh and Nikki Singh Revocable Trust (the "Revocable Trust") for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by the Revocable Trust except to the extent of his pecuniary interest therein.
- [F5]One-fourth of the shares subject to the option vested on November 23, 2006 and one forty-eighth of the shares shall vest monthly thereafter.
- [F6]Pursuant to the Merger Agreement, each outstanding and unexercised option to purchase shares of Transcept common stock outstanding and unexercised was assumed by Novacea and became an option to purchase that number of shares of Novacea common stock equal to the number of shares of Transcept common stock subject to the option multiplied by 0.141340.
- [F7]The option vests in forty-eight equal monthly installments beginning on March 26, 2007.
- [F8]The warrant is immediately exercisable.
- [F9]Pursuant to the Merger Agreement, each outstanding warrant to purchase shares of Transcept preferred stock or common stock outstanding was assumed by Novacea and became a warrant to purchase that number of shares of Novacea common stock equal to the number of shares of Transcept common stock, or the number of shares of Transcept common stock issuable upon conversion of Transcept preferred stock, issuable upon exercise of the Transcept warrant multiplied by 0.141340.
Documents
Issuer
Transcept Pharmaceuticals Inc
CIK 0001178711
Entity typeother
Related Parties
1- filerCIK 0001454351
Filing Metadata
- Form type
- 4
- Filed
- Feb 2, 7:00 PM ET
- Accepted
- Feb 3, 6:47 PM ET
- Size
- 18.3 KB